QUOTE AND NEWS
MedPage Today  Aug 25  Comment 
(MedPage Today) -- The FDA today approved a new low-dose formulation of diclofenac (Zorvolex) for the treatment of osteoarthritis pain, manufacturer Iroko Pharmaceuticals announced.
newratings.com  Aug 25  Comment 
Novartis experts and future scientific leaders meet at International BioCamp 2014 to consider 'The Race Against Time' Novartis International AG / Novartis experts and future scientific leaders meet at International BioCamp 2014 to...
newratings.com  Aug 22  Comment 
BRUSSELS (dpa-AFX) - Swiss stocks inched lower on Friday but outperformed slumping European markets ahead of a closely watched speech from European Central Bank President Mario Draghi. The Swiss Market Index eased 0.18 percent to 8,554, with...
Jutia Group  Aug 21  Comment 
[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on...
FiercePharma  Aug 21  Comment 
Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.
newratings.com  Aug 20  Comment 
Novartis provides drug candidate compounds to TB Alliance Novartis International AG / Novartis provides drug candidate compounds to TB Alliance . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for...
newratings.com  Aug 19  Comment 
BRUSSELS (dpa-AFX) - Swiss stocks extended recent gains on Tuesday, led by strong performances from some of the nation's largest companies. The Swiss Market Index added 0.85 percent to 8525.38, and is outperforming other European markets...
newratings.com  Aug 19  Comment 
BASEL (dpa-AFX) - Israel-based Elbit Imaging Ltd. (EMITF) noted Tuesday of its unit Elbit Medical Technologies Ltd.'s announcement that Gamida Cell Ltd., in which Elbit Medical holds approximately 30.8 percent of the voting power, as well as...
TheStreet.com  Aug 19  Comment 
NEW YORK (TheStreet) -- Shares of Novartis are up 0.88% to $88.27 in pre-market trade after it was reported that the Swissadrugmmaker agreed to take a 15% stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could...
FierceBiotech  Aug 19  Comment 
Novartis is forging ahead with a prospective stem cell biotech buyout, agreeing to pay $35 million to grab a sizable equity stake in Gamida Cell while executing a short term option deal that will allow the pharma giant the right to gobble up the...




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki